Business Context and Reporting Period
This Form 8-K Current Report was filed by Armata Pharmaceuticals, Inc. (ARMP) on December 2, 2024. The report addresses the departure of a senior officer and the execution of a separation agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements related to a separation.
Material Changes
- Executive Departure: Mina Pastagia, M.D., the Company's Chief Medical Officer, concluded her employment effective November 13, 2024.
- Separation Agreement: On December 2, 2024, the Company entered into a Separation and Release Agreement with Dr. Pastagia.
- Compensation Impact: Dr. Pastagia is entitled to continued payment of her base salary for twelve (12) months following the termination date, subject to her compliance with the agreement and non-revocation of the release.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of general corporate risks. The primary contingency noted is that the severance payments are conditional upon Dr. Pastagia's compliance with the Separation Agreement and her failure to revoke the release of claims.
Investor Verification Checklist
- Verify the exact base salary amount of Dr. Pastagia to calculate the total severance liability.
- Review the full text of the Separation and Release Agreement (Exhibit 10.1) for additional terms, such as benefits continuation or non-compete clauses.
- Confirm the Company's current cash position to assess the impact of the 12-month salary obligation.
- Monitor for the appointment of a new Chief Medical Officer to ensure continuity of clinical operations.